Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Byeong-Bae | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Lee, Won Sik | - |
dc.date.accessioned | 2022-07-15T20:18:57Z | - |
dc.date.available | 2022-07-15T20:18:57Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-11 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155958 | - |
dc.description.abstract | There is no standard salvage chemotherapy for relapsed or refractory peripheral T-cell lymphomas (PTCLs). Gemcitabine combined with cisplatin has been known as an effective regimen for lymphoma treatment in the salvage setting. We investigated the efficacy and toxicity of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory PTCLs in search of a more effective and less toxic therapy. Patients with relapsed or refractory PTCLs with more than one previous regimen were eligible. Treatment consisted of gemcitabine 1000 mg/m(2) intravenously (i.v.) on days 1 and 8, dexamethasone 40 mg orally on days 1-4, and cisplatin 70 mg/m(2) i.v. on day 1, and then every 21 days. Patients could proceed to autologous stem cell transplantation (ASCT) after four cycles of GDP or receive up to six treatment cycles. Twenty-five eligible patients were evaluated for toxicity and response. The diagnoses of participants included 14 cases of PTCL-not otherwise specified (NOS) (56 %) and four cases of angioimmunoblastic T-cell lymphoma (16 %) among others. The median age of the patients was 59 years (range 20-75 years). After treatments with GDP, which delivered a median of four GDP cycles, there were 12 patients with complete responses (CR; 48 %) and six with partial responses (PR; 24 %). The overall response rate (RR) was 72 %. Four patients preceded to ASCT, and three patients finally achieved CR. The median progression free survival was 9.3 months (95 % confidence interval (CI); 4.1-14.6) with a median follow-up duration of 27.1 months. In a total of 86 cycles of GDP, grade 3 or 4 neutropenia and thrombocytopenia occurred in 16.3 and 12.8 % of cycles, respectively. Three patients (3.3 %) experienced febrile neutropenia. GDP is a highly effective and optimal salvage regimen for relapsed or refractory PTCLs and can be administered with acceptable toxicity. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.title | Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Byeong-Bae | - |
dc.identifier.doi | 10.1007/s00277-015-2468-y | - |
dc.identifier.scopusid | 2-s2.0-84941993163 | - |
dc.identifier.wosid | 000361396600010 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.94, no.11, pp.1845 - 1851 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 94 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1845 | - |
dc.citation.endPage | 1851 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | METHYLPREDNISOLONE GEM-P | - |
dc.subject.keywordPlus | TRANSPLANTATION | - |
dc.subject.keywordPlus | CYTARABINE | - |
dc.subject.keywordPlus | ETOPOSIDE | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | FEATURES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | Salvage therapy | - |
dc.subject.keywordAuthor | Peripheral T-cell lymphoma | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00277-015-2468-y | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.